

<p>Informazione Regolamentata n. 0957-31-2025</p>	<p>Data/Ora Inizio Diffusione 16 Aprile 2025 18:12:12</p>	<p>Euronext Milan</p>
---	---	-----------------------

Societa' : DIASORIN

Identificativo Informazione Regolamentata : 204316

Utenza - referente : DIASORINN01 - Ulisse Spada - Valerio Giovanni Vaccarone

Tipologia : 2.5

Data/Ora Ricezione : 16 Aprile 2025 18:12:12

Data/Ora Inizio Diffusione : 16 Aprile 2025 18:12:12

Oggetto : Communication on total amount of voting rights

Testo del comunicato

See attachment.

DIASORIN: COMMUNICATION ON TOTAL AMOUNT OF VOTING RIGHTS PURSUANT TO ARTICLE 85-BIS, PARAGRAPH 4-BIS, OF CONSOB REGULATION NO. 11971/1999

Saluggia, April 16, 2025 – In accordance with Article 85-bis paragraph 4-bis, of Consob Regulation no. 11971/1999 Diasorin (FTSE MIB: DIA) hereby communicates the total amount of the voting rights, together with the number of shares making up the share capital, as of April 15, 2025 (record date):

	Number of shares making up share capital	No. of voting rights	Euro
Total amount, of which:	55,948,257	88,251,090*	55,948,257
Ordinary shares without increased voting rights ISIN IT0003492391 (regular dividend) Current coupon: no. 20	23,645,424	23,645,424	-
Ordinary shares with increased voting rights ISIN IT0005188385 (regular dividend) Current coupon: no. 20	32,302,833	64,605,666	-

* As previously disclosed to the market, as a result of the approval of the proposal to enhance the current loyalty shares system by the Extraordinary Shareholders' Meeting of February 28, 2025, the right of withdrawal was exercised for 943,617 shares, for which the voting right is currently not exercisable.

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 35 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasorin.com

For additional information, please contact:

Riccardo Fava
 Corporate Vice President Communication & Investor Relations
riccardo.fava@diasorin.com

Eugenia Ragazzo
 Corporate Investor Relations & ESG Analyst
eugenia.ragazzo@diasorin.com

Fine Comunicato n.0957-31-2025

Numero di Pagine: 3